Pivtorak K. V., Marchuk O. V.

LITERATURE REVIEWS

Scentific article

In this paper, an analysis of modern scientific literary sources was carried out regarding common mechanisms of development of sarcopenia and non-alcoholic fatty liver disease. Patients with non-alcoholic liver disease have a high prevalence of sarcopenia, which is characterized by progressive loss of muscle mass and function and affects quality of life and disease prognosis. The article highlights various variants of the pathogenesis of sarcopenia and NAFLD. It is generally known that the liver takes part in the metabolism and accumulation of nutrients, the synthesis and detoxification of many biologically active substances, hormones, cytokines, and ammonia detoxification. Accumulated data indicate that liver dysfunction leads to an imbalance between muscle protein synthesis and its lysis. Other signaling molecules (growth hormone, insulin-like growth factor-1, some myokines) produced in large quantities, as well as oxidative stress, trigger common signaling pathways that promote inflammation and fibrosis. Abdominal and visceral adiposity have been shown to have a strong effect on suppression of growth hormone secretion, and obese patients with the lowest levels of this hormone have the most severe metabolic complications. Therefore, the reduced levels of growth hormone and insulin-like growth factor-1 seen in obese patients may be detrimental to both skeletal muscle and liver, promoting ectopic fat accumulation. Skeletal muscle plays a key role in insulin signaling as the primary tissue responsible for insulin-mediated glucose utilization. Decreased skeletal muscle mass can cause insulin resistance and impaired carbohydrate metabolism, which ultimately leads to NAFLD and its characteristic components and signs. Chronic inflammation and oxidative stress simultaneously cause muscle atrophy and lead to hepatocyte stress reactions, which, in turn, contributes to the progression of liver fibrosis associated with steatohepatitis and nonalcoholic fatty liver disease. A pathogenetic connection between sarcopenia and NAFLD has been established. Numerous studies have proven that aerobic physical exercises, reducing the level of systemic inflammation contribute to reducing the loss of muscle components of body weight and improving clinical and laboratory indicators in NAFLD.

liver,non-alcoholic fatty liver disease,sarcopenia,insulin-like growth factor,physical activity

1. Lee K, Shin Y, Huh J, Sung YS, Lee IS, Yoon KH, et al. Recent Issues on Body Composition Imaging for Sarcopenia Evaluation. Korean J Radiol. 2019 Feb;20(2):205-217.
2. Pivtorak KV. Endotelialna dysfunktsiia ta nealkoholna zhyrova khvoroba pechinky. Vinnytsia: Nova knyha; 2022. 192 s. [in Ukrainian].
3. Yu R, Shi Q, Liu L, Chen L. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. BMC Gastroenterol. 2018 Apr 19;18(1):51. DOI: 10.1186/s12876-018-0776-0.
4. Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol. 2018 Jan-Feb;24(1):12-17. DOI: 10.4103/sjg.SJG_237_17.
5. Pan X, Han Y, Zou T, Zhu G, Xu K, Zheng J, et al. Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis. Dig Dis. 2018;36(6):427-436. DOI: 10.1159/000491015.
6. Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019 Oct;54(10):845-859. DOI: 10.1007/s00535-019-01605-6.
7. Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123-131. DOI: 10.1016/j.jhep.2016.08.019.
8. Fernández-Mincone T, Contreras-Briceño F, Espinosa-Ramírez M, García-Valdés P, López-Fuenzalida A, Riquelme A, et al. Nonalcoholic fatty liver disease and sarcopenia: Pathophysiological connections and therapeutic implications. Expert Review of Gastroenterology & Hepatology. 2020;14(12):1141-1157. DOI: 10.1080/17474124.2020.1810563.
9. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. DOI: 10.1093/ageing/ afq034.
10. Pivtorak K, Monastyrskyi V, Kuleshov O, Fedzhaga I, Pivtorak N. Relationship between sarcopenia and osteoporosis in non-alcoholic fatty liver disease. Georgian Med News. 2022 May;326:12-17.
11. Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017 Dec;66(6):2055-2065. DOI: 10.1002/hep.29420.
12. Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev. 2018 Jun 11;2018:9547613.
13. Pan XY, Liu WY, Zhu PW, Li G, Tang LJ, Gao F, et al. Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. Hepatol Int. 2022;2022:201.
14. Gan D, Wang L, Jia M, Ru Y, Ma Y, Zheng W, et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr. 2020 Apr;39(4):1124-1130. DOI: 10.1016/j.clnu.2019.04.023.
15. Kashiwagi K, Takayama M, Fukuhara K, Shimizu-Hirota R, Chu PS, Nakamoto N, et al. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity. Clin Nutr ESPEN. 2020 Aug;38:86-93. DOI: 10.1016/j.clnesp.2020.05.025.
16. Bahat G, Kilic C, Ozkok S, Ozturk S, Karan MA. Associations of sarcopenic obesity versus sarcopenia alone with functionality. Clin Nutr. 2021 May;40(5):2851-2859. DOI: 10.1016/j.clnu.2021.04.002.
17. Kashiwagi K, Takayama M, Ichikawa H, Takaishi H, Iwao Y, Kanai T. A significant association of non-obese non-alcoholic fatty liver disease with osteosarcopenic obesity in females 50 years and older. Clin Nutr ESPEN. 2021 Apr;42:166-172.
18. Pivtorak KV. Antropometrychne doslidzhennia khvorykh na nealkoholnu zhyrovu khvorobu. Zaporozhskyi medytsynskyi zhurnal. 2017;19(5):623-628. [in Ukrainian].
19. Pivtorak KV. Component composition of body weight in patients with non-alcoholic fatty liver disease. Biomedical and Biosocial Anthropology. 2019;35:5-10.
20. Cai C, Song X, Chen Y, Chen X, Yu C. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Int. 2020 Jan;14(1):115-126.
21. Trenell MI, Marchesini G. Does the liver accelerate ageing: Talking muscles and liver? J Hepatol. 2017 Jan;66(1):8-10. DOI: 10.1016/j. jhep.2016.10.018.
22. Ghoch M, Pellegrini M. Why should sarcopenic obesity be included in a routine assessment during weight-management programmes? Front Endocrinol (Lausanne). 2022;13:962895. DOI: 10.3389/fendo.2022.962895.
23. Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun. 2021 Jan 12;12(1):330.
24. Morton RW, Murphy KT, McKellar SR, Schoenfeld BJ, Henselmans M, Helms E, et al. A systematic review, meta-analysis and metaregression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018 Mar;52(6):376-384.
25. Kemmler W, Weineck M, Kohl M, von Stengel S, Giessing J, Fröhlich M, et al. High Intensity Resistance Exercise Training to Improve Body Composition and Strength in Older Men With Osteosarcopenia. Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). Front Sports Act Living. 2020 Jan 28;2:4.
26. Lichtenberg T, von Stengel S, Sieber C, Kemmler W. The Favorable Effects of a High-Intensity Resistance Training on Sarcopenia in Older Community-Dwelling Men with Osteosarcopenia: The Randomized Controlled FrOST Study. Clin Interv Aging. 2019 Dec 16;14:2173-2186.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 79-86 pages, index UDK 616.36-003.826+616.74-007.23+616.71-007.234

10.29254/2077-4214-2022-3-166-79-86